Skip to content

    Gland Pharma Q1 FY27 earnings call

    GLAND
    Healthcare·10 Aug 2026
    Management Summary

    Gland Pharma delivered a strong Q1 FY27 with robust revenue and profit growth, driven by strong performance in both CDMO and B2B segments and key geographic markets like the US. The company secured a significant strategic manufacturing agreement and continues to invest in capacity expansion and R&D for future growth, despite minor headwinds from forex losses and supply disruptions in some ROW markets.

    Highlights

    8

    • Revenues grew 20% year-on-year to INR 18,003 million.

    • Adjusted EBITDA stood at INR 5,102 million with margins of 28%, up from 25% in Q1 FY26.

    • Profit after tax grew 47% year-on-year to INR 3,170 million, with PAT margin of 18%.

    • Secured a strategic manufacturing and supply agreement with a revenue potential of USD 90-100 million from CY29.

    • CDMO business grew 20% year-on-year to INR 8,915 million, contributing 50% of total revenues.

    • B2B business grew 19% year-on-year to INR 9,088 million, also contributing 50% of total revenues.

    • US revenues grew 32% year-on-year to INR 9,810 million.

    • Net cash surplus of INR 32,939 million.

    Concerns

    4

    • Forex loss of INR 36 million in Q1 FY27, compared to a gain of INR 508 million in Q4 FY26 and INR 39 million in Q1 FY26.

    • Supply disruptions in Saudi Arabia impacted Rest of World (ROW) revenues, which were broadly in line with last year.

    • Award of NUPCO tenders delayed.

    • Cenexi operations impacted by summer heat wave in Europe.

    Key financials

    Single quarter

    11 metrics
    1. 01Revenue18,003 Mn+20%YoY
    2. 02Adjusted EBITDA5,102 Mn
    3. 03Adjusted EBITDA Margin28%
    4. 04Profit After Tax3,170 Mn+47%YoY
    5. 05PAT Margin18%

    Segment breakdown

    United States
    9,810 Mn27.2%
    B2B Business
    9,088 Mn25.2%
    CDMO Business
    8,915 Mn24.7%
    Europe & Other Regulatory Markets
    4,488 Mn12.4%
    Rest of World (ROW)
    3,039 Mn8.4%
    India
    666 Mn1.8%
    Cenexi
    48 Mn0.1%
    Treemap· Share of Revenue

    Order Book

    high confidence

    Total Value

    USD 90 million

    as of 2026-06-30

    range

    Execution

    Revenue generation anticipated from calendar year 2029.

    Composition

    Mix3 geographys
    • U.S. Market60.0%
    • European Market35.0%
    • Rest of World20.0%

    Share of order book by geography · partial disclosure (115.0% of book)

    "The strategic manufacturing and supply agreement with a global pharmaceutical company for sterilized injectables has a revenue potential of USD 90-100 million from CY29, with 60% for the US market and 30-35% for Europe."

    Source:
    Prepared remarks

    Capital allocation

    4
    high confidence
    CategoryHeadline
    Capex

    ₹1,132 million this quarter · ₹5,500 million (FY27) planned

    new plan — Earlier announced INR 2,000 crores program, now specifying this year's spend and additional project.

    Debt

    Net ₹32,939 million

    M&A

    China-based development company (for liposomal product)

    acquisition · signed

    Liquidity

    Cash ₹35,466 million

    Company is a net cash surplus with a net cash position of INR 32,939 million.

    Guidance & targets

    8
    CategoryTargetPriority
    Revenue Growth
    Overall Revenue Growth CAGR
    around 20%
    		Medium
    Revenue Growth
    Current Year Revenue Growth
    15%
    		High
    EBITDA Margin
    Consolidated EBITDA Margin
    30%
    		Medium
    EBITDA Margin
    Consolidated EBITDA Margin
    35%
    		Low
    Strategic Manufacturing Agreement
    Revenue Potential
    USD 90-100 million
    		High
    Cenexi
    Cenexi Revenue
    near EUR200 million
    		High
    NDDS Project
    Commercialization Timeline
    2029
    		High
    NDDS Project
    Revenue Potential
    USD 25-30 million
    		High

    What to watch in Q2 FY27

    5

    Overall Growth CAGR Clarity

    Next quarter (September/October)
    CurrentRe-evaluating from 15% to ~20%
    TargetClear 4-year CAGR guidance

    Why it matters

    Provides long-term growth outlook for the company and indicates management's revised expectations.

    Probably we'll next quarter have more clarity on the growth for the next 4 years. But as of now, with this new contract in place, we are looking at 20% -- around 20% growth next 4 years.

    Risks & concerns

    4
    RiskSeverity

    Supply disruptions in Saudi Arabia

    Impacted Rest of World (ROW) revenues, which were broadly in line with last year. — Management acknowledged

    medium

    Delay in NUPCO tenders award

    The award of NUPCO tenders has been delayed, results expected shortly. — Management acknowledged

    medium

    Forex loss in Q1 FY27

    INR 36 million forex loss compared to gains in previous quarters, impacting PAT. — Management acknowledged

    low

    Summer heat wave impact on Cenexi operations

    Disrupted activities at Cenexi's Fontenay facility, though Q2 is expected to be better. — Management acknowledged

    low

    Q&A highlights

    8

    “So this is a specialty pharma global company. So the revenue is a mix of generics as well as complex and specialty pharma. So probably 30% 40% of the revenue comes from specialty business. So the portfolio of what getting transferred to these are all from Indian sites, the manufacturing happening at Indian sites. ... The Cenexi plays a little part in this as well. ... And the revenues will ramp up from '29 because the filings will start happening from next year.”

    Clarified the nature of the significant new contract, its product mix, manufacturing location, and the expected timeline for revenue contribution, including Cenexi's role.

    asked by Saion Mukherjee

    2 min read5 chapters

    Detailed Narrative

    01

    Strong Q1 FY27 Performance Driven by CDMO and B2B Growth

    Gland Pharma commenced FY27 with robust financial results, reporting revenues of INR 18,003 million, a 20% year-on-year increase. This growth was equally supported by the CDMO and B2B segments, each contributing 50% to total revenues and growing 20% and 19% respectively. Adjusted EBITDA reached INR 5,102 million, translating to a healthy 28% margin, up from 25% in the prior year, while profit after tax surged 47% year-on-year to INR 3,170 million.

    02

    Strategic Expansion in CDMO and Product Portfolio

    The company secured a significant strategic manufacturing and supply agreement with a global pharmaceutical company for sterilized injectables, with a revenue potential of USD 90-100 million anticipated from calendar year 2029. This agreement covers 55 SKUs across oncology and non-oncology products. Additionally, Gland Pharma entered a strategic collaboration with Neuland Laboratories for sterile APIs for microparticle depot products and in-licensed a niche liposomal product for US and European markets, with revenue contribution expected from FY30.

    03

    Geographic Performance and Market Dynamics

    The United States remained the largest market, delivering strong growth of 32% year-on-year to INR 9,810 million, driven by new CDMO launches and existing product volume expansion. Europe and other regulatory markets also saw an 11% growth to INR 4,488 million. However, Rest of World revenues were flat at INR 3,039 million, impacted by supply disruptions in Saudi Arabia and delays in NUPCO tender awards.

    04

    Capacity Expansion and R&D Investments

    Gland Pharma continues its aggressive capital expenditure program, spending INR 1,132 million in Q1 FY27, primarily for capacity expansion across vial, ophthalmic, BFS lines, and liposome products. The company plans to spend approximately INR 550 crores on capex this fiscal year, including INR 165 crores for a new isolator line in its oncology plant. R&D investments remained healthy at INR 772 million, representing 4% of consolidated revenue, focusing on complex injectables, peptides, and advanced drug delivery platforms.

    05

    Cenexi Operations and Future Outlook

    Cenexi, now fully integrated into the CDMO business, reported EUR 48 million in revenue and EUR 2 million in EBITDA for the quarter. Despite disruptions from a summer heat wave, the Fontenay facility performed well, and the company aims for double-digit EBITDA margins for Cenexi by year-end. Management reiterated a target of 30% consolidated EBITDA margins in the near term, aspiring for 35% in the midterm, and is re-evaluating its 4-year CAGR guidance upwards from 15% to around 20%.

    This is an AI-generated summary of a publicly available earnings call transcript.